Skip to Content

Neuromuscular Disorders Clinical Trials

Compassionate Use of 3, 4-Diaminopyridine in Lambert Eaton Myasthenic Syndrome
Aims: Treatment of Lambert-Eaton Myasthenic Syndrome
Principal Investigator:
David Randall, DO
NorthShore Project Number:  EH02-041
Contact:  Please call 847.503.4322 with questions regarding the study
Open to Enrollment: Yes

An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus
Aims: The primary objective of the study is to provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is to assess the long-term safety of amifampridine.
Principal Investigator: Alexandru Barboi, MD
NorthShore Project Number: EH16-121
Contact: Please call 847.570.4046 with questions regarding the study
Open to Enrollment: Yes

Rapid Number Naming Performance in Myasthenia Gravis (MG) using the King-Devick (K-D) Test
The purpose of this study is to investigate the change in K-D rapid eye movement performance test with initiation or change in MG treatment and clinical improvement.  This study also aims to define the relation of K-D test performance to standard clinical measures of MG in both visual and MG-specific quality of life scores.
Principal Investigator:
John Pula, MD
NorthShore Project Number:
Please call 224.251.2020 with questions regarding the study.
Open to Enrollment: